drugset / Trial / NCT00351910

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

NCT00351910 ↗

Phase 3 Completed 494 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2006-05
Primary completion
—
Completion
2007-04

Outcome

Met primary endpoint

paper Mean change from randomization to week 6 in MADRS score was -15.26 and -14.94 for quetiapine XR 150 mg/day and 300 mg/day, respectively (both p < .01 vs. placebo [-12.21]). PMID 19358791 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 150 mg —
Subject Quetiapine Small molecule 300 mg —
Background Amitriptyline Small molecule — —
Background Bupropion Small molecule — —
Background Citalopram Small molecule — —
Background Duloxetine Small molecule — —
Background Escitalopram Small molecule — —
Background Fluoxetine Small molecule — —
Background Paroxetine Small molecule — —
Background Sertraline Small molecule — —
Background Venlafaxine Small molecule — —